Antihyperlipidemic Activity of Glycoconjugated Phthalimides in Mice Submitted to a Model of Dyslipidemia and Insulin Resistance

Chem Biodivers. 2022 Oct;19(10):e202200119. doi: 10.1002/cbdv.202200119. Epub 2022 Sep 27.

Abstract

Alterations in lipid and lipoprotein metabolism are factors that trigger several negative metabolic complications. Hyperlipidemia is the starting point for the development of comorbidities of the cardiovascular system, such as atherosclerosis. The search for compounds that reduce high levels of total cholesterol and triglycerides has been widely reported in several publications in the literature. Phthalimide derivatives have been extensively researched with various biological actions. In this study we evaluated the antihyperlipidemic ability of three phthalimide derivatives (FGT-2, FGT-3 and FGT-4) on a model of obesity and insulin resistance in mice. The animals were submitted to a hyperlipid diet for 60 days. On the thirtieth day they were treated with phthalimides (20 mg/kg). The positive control group was treated with Simvastatin (20 mg/kg) and the negative control received only the carboxymethylcellulose vehicle. Biochemical and histological analyzes of all groups were analyzed. The animals treated with phthalimidic derivatives had a reduction in total cholesterol, low density and very low density lipoproteins (LDL-c and VLDL-c), triglycerides and fasting glycemia when compared to the negative control group. The treated animals also showed good results when analyzing the atherogenic indexes Castelli i and II and the ratio Triglycerides/HDL-c. In the oral glucose tolerance test and in the insulin tolerance test, animals treated with phthalimides were more sensitive to the action of the hormone regulating carbohydrate uptake. In the evaluation of the transaminases (AST/ALT), the animals of the group treated with phthalimides presented a lower elevation than the other groups of the experiment, the same observed with the uric acid evaluation. Histological analyzes were performed on liver, kidney, heart and pancreas samples. The groups treated with the compounds FGT-2 and FGT3 presented discrete alterations in the liver and kidney. FGT-4 did not present histological alterations for both tissues and the three phthalimide derivatives did not cause alterations in the other organs. These results suggest that the phthalimides tested can act as antihyperlipidemic agents and have a pleiotropic action, by acting also reducing glycemia in insulin resistance model mimicking diabetes mellitus type 2. These compounds may appear as a new approach in the treatment of obesity and complications, which are multifaceted.

Keywords: cyclic imides; insulin resistance; obesity; phthalimides.

MeSH terms

  • Animals
  • Carboxymethylcellulose Sodium
  • Cholesterol, LDL
  • Diabetes Mellitus, Type 2*
  • Dyslipidemias* / drug therapy
  • Hormones
  • Hypolipidemic Agents / pharmacology
  • Hypolipidemic Agents / therapeutic use
  • Insulin Resistance*
  • Insulins*
  • Lipoproteins, VLDL
  • Mice
  • Obesity / drug therapy
  • Phthalimides / pharmacology
  • Simvastatin
  • Transaminases
  • Triglycerides
  • Uric Acid

Substances

  • Hypolipidemic Agents
  • phthalimide
  • Cholesterol, LDL
  • Uric Acid
  • Carboxymethylcellulose Sodium
  • Triglycerides
  • Phthalimides
  • Lipoproteins, VLDL
  • Simvastatin
  • Hormones
  • Transaminases
  • Insulins